Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Yarrow Bioscience, Inc.VYNE · Entity 6871 | Director · PRESIDENT AND CEO | July 23, 2026 | July 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Yarrow Bioscience, Inc.
Report date July 23, 2026 · Filed July 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 347,174 |
Reported balance
After 2026-07-23 transaction · row 1
1 source rowRow 1 · 2026-07-23 · Tax withholding · Disposed 79,391 · Balance 347,174 F1: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Foamix Pharmaceuticals Ltd.
Report date March 09, 2020 · Filed March 11, 2020
Section 16 reporting ended · disclosed 2020-03-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2020-03-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-03-09 · Disposition to issuer · Disposed 90,902 · Balance 233,126 F1: On March 9, 2020 (the "Closing Date"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the "Merger Agreement"), by and among Menlo Therapeutics Inc., a Delaware corporation ("Menlo"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo ("Merger Sub"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the "Merger"). At the effective time of the Merger (the "Effective Time"), each ordinary share, par value NIS 0.16 per share, of Foamix ("Foamix Shares") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the "Exchange Ratio") of common stock of Menlo ("Menlo Common Stock") and (ii) one contingent stock right (continued in footnote 2) F2: (a "CSR"; and collectively, the "CSRs") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the "CSR Agreement"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the "Merger Consideration"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement. Row 2 · 2020-03-09 · Disposition to issuer · Disposed 233,126 · Balance 0 F3: Represents Foamix restricted stock unit awards ("Foamix RSUs") that were outstanding immediately prior to the Effective Time, each of which by its terms represented a contingent right to receive one Foamix Share. Each Foamix RSU was assumed by Menlo and converted into a restricted stock unit award relating to Menlo Common Stock (an "Adjusted RSU Award") and has the same terms and conditions as applied to the Foamix RSU immediately prior to the Effective Time. The Adjusted RSU Award will settle in the number of shares of Menlo Common Stock equal to the product obtained by multiplying (i) the number of Foamix Shares subject to the Foamix RSU immediately prior to the Effective Time by (ii) the Exchange Ratio. If the CSRs become convertible, each person holding a Foamix RSU immediately prior to the Effective Time will get additional Adjusted RSU Awards based on the additional shares of Menlo Common Stock that each ordinary Foamix Share will get upon conversion of a CSR. |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $7.98 · Expires 2024-06-09 | Direct | 0 |
Reported balance
After 2020-03-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-03-09 · Disposition to issuer · Disposed 18,750 · Balance 0 F5: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F4: The Options vested over a period of four years from June 9, 2014 (25% on each anniversary of such date). |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $7.14 · Expires 2025-11-10 | Direct | 0 |
Reported balance
After 2020-03-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-03-09 · Disposition to issuer · Disposed 236,810 · Balance 0 F5: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F6: The Options vested over a period of four years from November 10, 2015 (25% on the first anniversary of such date and 6.25% every three months thereafter). |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $6.04 · Expires 2026-03-01 | Direct | 0 |
Reported balance
After 2020-03-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-03-09 · Disposition to issuer · Disposed 60,000 · Balance 0 F5: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F7: The ordinary shares underlying this option vest over a period of four years (25% on March 1, 2017 and 6.25% every three months thereafter) ending March 31, 2020. |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $10.22 · Expires 2027-01-01 | Direct | 0 |
Reported balance
After 2020-03-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-03-09 · Disposition to issuer · Disposed 71,369 · Balance 0 F5: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F8: The ordinary shares underlying this option vest over a period of four years (25% on January 1, 2018 and 6.25% every three months thereafter) ending March 31, 2021. |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $5.76 · Expires 2027-08-08 | Direct | 0 |
Reported balance
After 2020-03-09 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-03-09 · Disposition to issuer · Disposed 327,720 · Balance 0 F5: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F9: The ordinary shares underlying this option vest over a period of four years (25% on August 8, 2018 and 6.25% every three months thereafter) ending September 30, 2021. |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $5.06 · Expires 2028-02-27 | Direct | 0 |
Reported balance
After 2020-03-09 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-03-09 · Disposition to issuer · Disposed 70,187 · Balance 0 F5: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F10: The ordinary shares underlying this option vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending March 31, 2022. |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.77 · Expires 2029-01-01 | Direct | 0 |
Reported balance
After 2020-03-09 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-03-09 · Disposition to issuer · Disposed 170,993 · Balance 0 F5: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F11: The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2020 and 6.25% every three months thereafter) ending March 31, 2023. |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $4.03 · Expires 2030-02-24 | Direct | 0 |
Reported balance
After 2020-03-09 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-03-09 · Disposition to issuer · Disposed 240,912 · Balance 0 F5: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F12: The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2021 and 6.25% every three months thereafter) ending March 31, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 9, 2020 (the "Closing Date"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the "Merger Agreement"), by and among Menlo Therapeutics Inc., a Delaware corporation ("Menlo"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo ("Merger Sub"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the "Merger"). At the effective time of the Merger (the "Effective Time"), each ordinary share, par value NIS 0.16 per share, of Foamix ("Foamix Shares") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the "Exchange Ratio") of common stock of Menlo ("Menlo Common Stock") and (ii) one contingent stock right (continued in footnote 2)
F2: (a "CSR"; and collectively, the "CSRs") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the "CSR Agreement"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the "Merger Consideration"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement.
F3: Represents Foamix restricted stock unit awards ("Foamix RSUs") that were outstanding immediately prior to the Effective Time, each of which by its terms represented a contingent right to receive one Foamix Share. Each Foamix RSU was assumed by Menlo and converted into a restricted stock unit award relating to Menlo Common Stock (an "Adjusted RSU Award") and has the same terms and conditions as applied to the Foamix RSU immediately prior to the Effective Time. The Adjusted RSU Award will settle in the number of shares of Menlo Common Stock equal to the product obtained by multiplying (i) the number of Foamix Shares subject to the Foamix RSU immediately prior to the Effective Time by (ii) the Exchange Ratio. If the CSRs become convertible, each person holding a Foamix RSU immediately prior to the Effective Time will get additional Adjusted RSU Awards based on the additional shares of Menlo Common Stock that each ordinary Foamix Share will get upon conversion of a CSR.
F4: The Options vested over a period of four years from June 9, 2014 (25% on each anniversary of such date).
F5: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options.
F6: The Options vested over a period of four years from November 10, 2015 (25% on the first anniversary of such date and 6.25% every three months thereafter).
F7: The ordinary shares underlying this option vest over a period of four years (25% on March 1, 2017 and 6.25% every three months thereafter) ending March 31, 2020.
F8: The ordinary shares underlying this option vest over a period of four years (25% on January 1, 2018 and 6.25% every three months thereafter) ending March 31, 2021.
F9: The ordinary shares underlying this option vest over a period of four years (25% on August 8, 2018 and 6.25% every three months thereafter) ending September 30, 2021.
F10: The ordinary shares underlying this option vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending March 31, 2022.
F11: The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2020 and 6.25% every three months thereafter) ending March 31, 2023.
F12: The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2021 and 6.25% every three months thereafter) ending March 31, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 06, 2020 Filed May 8, 2020 21:53 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantCommon Stock | 680,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-028034 · doc4.xml · nonDerivative · entry 1 Domzalski David · CIK 0001727794 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,247,213 F1 · shares: Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo Therapeutics Inc. F2 · shares: The awards vest over four years, 25% on June 30, 2021 and 6.25% every three months thereafter, ending on June 30, 2024. Read SEC document |
| April 06, 2020 Filed Apr 7, 2020 21:21 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | Tax withholdingCommon Stock | 11,772 | $1.40 | $16,480.80 |
DisclosureSEC source: 0001209191-20-023804 · doc4.xml · nonDerivative · entry 3 Domzalski David · CIK 0001727794 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 567,213 F4 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 21:21 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantCommon Stock | 249,588 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-023804 · doc4.xml · nonDerivative · entry 2 Domzalski David · CIK 0001727794 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 578,985 F3 · shares: Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo. F1 · price: As disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2020, following the receipt of certain clinical trial results, Menlo Therapeutics Inc. ("Menlo") issued additional shares of its common stock pursuant to certain contingent stock rights ("CSRs") issued in connection with the March 9, 2020 merger (the "Merger") of Menlo and Foamix Pharmaceuticals Ltd. ("Foamix"), including pursuant to CSRs held by the Reporting Person. The issuance of shares pursuant to the CSRs resulted in an adjustment to the effective exchange ratio applicable to the Merger, from 0.5924 to 1.8006 (the "Final Exchange Ratio"). Menlo derivative securities issued in exchange for Foamix derivative securities in connection with the Merger were also adjusted pursuant to their terms to give effect to the Final Exchange Ratio. The transactions reported in these line items reflect the additional shares and restricted stock unit (continued in footnote 2) F2 · price: (continued from footnote 1) awards that were received by the reporting person as a result of the foregoing. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 21:21 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantCommon Stock | 141,901 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-023804 · doc4.xml · nonDerivative · entry 1 Domzalski David · CIK 0001727794 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,397 F1 · price: As disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2020, following the receipt of certain clinical trial results, Menlo Therapeutics Inc. ("Menlo") issued additional shares of its common stock pursuant to certain contingent stock rights ("CSRs") issued in connection with the March 9, 2020 merger (the "Merger") of Menlo and Foamix Pharmaceuticals Ltd. ("Foamix"), including pursuant to CSRs held by the Reporting Person. The issuance of shares pursuant to the CSRs resulted in an adjustment to the effective exchange ratio applicable to the Merger, from 0.5924 to 1.8006 (the "Final Exchange Ratio"). Menlo derivative securities issued in exchange for Foamix derivative securities in connection with the Merger were also adjusted pursuant to their terms to give effect to the Final Exchange Ratio. The transactions reported in these line items reflect the additional shares and restricted stock unit (continued in footnote 2) F2 · price: (continued from footnote 1) awards that were received by the reporting person as a result of the foregoing. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 20:32 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | Tax withholdingCommon Stock | 4,456 | $2.68 | $11,942.08 |
DisclosureSEC source: 0001209191-20-022574 · doc4.xml · nonDerivative · entry 1 Domzalski David · CIK 0001727794 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,496 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 21:56 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Options · Derivative | 142,716 | Not disclosed Strike: $6.81 | Not disclosed |
DisclosureSEC source: 0001209191-20-018224 · doc4.xml · derivative · entry 10 Domzalski David · CIK 0001727794 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,716 Underlying: Common Stock · 142,716 shares Expires 2030-02-24 F1 · price: Received in or in connection with the merger of Foamix Pharmaceuticals Ltd. ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. ("Menlo"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020. F8 · derivative.exercise_date: The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2021 and 6.25% every three months thereafter) ending March 31, 2024. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 21:56 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Options · Derivative | 101,296 | Not disclosed Strike: $6.37 | Not disclosed |
DisclosureSEC source: 0001209191-20-018224 · doc4.xml · derivative · entry 9 Domzalski David · CIK 0001727794 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,296 Underlying: Common Stock · 101,296 shares Expires 2029-01-01 F1 · price: Received in or in connection with the merger of Foamix Pharmaceuticals Ltd. ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. ("Menlo"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020. F7 · derivative.exercise_date: The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2020 and 6.25% every three months thereafter) ending March 31, 2023. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 21:56 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Options · Derivative | 41,578 | Not disclosed Strike: $8.55 | Not disclosed |
DisclosureSEC source: 0001209191-20-018224 · doc4.xml · derivative · entry 8 Domzalski David · CIK 0001727794 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,578 Underlying: Common Stock · 41,578 shares Expires 2028-02-27 F1 · price: Received in or in connection with the merger of Foamix Pharmaceuticals Ltd. ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. ("Menlo"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020. F6 · derivative.exercise_date: The ordinary shares underlying this option vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending March 31, 2022. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 21:56 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Options · Derivative | 194,141 | Not disclosed Strike: $9.73 | Not disclosed |
DisclosureSEC source: 0001209191-20-018224 · doc4.xml · derivative · entry 7 Domzalski David · CIK 0001727794 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,141 Underlying: Common Stock · 194,141 shares Expires 2027-08-08 F1 · price: Received in or in connection with the merger of Foamix Pharmaceuticals Ltd. ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. ("Menlo"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020. F5 · derivative.exercise_date: The ordinary shares underlying this option vest over a period of four years (25% on August 8, 2018 and 6.25% every three months thereafter) ending September 30, 2021. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 21:56 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Options · Derivative | 42,278 | Not disclosed Strike: $17.25 | Not disclosed |
DisclosureSEC source: 0001209191-20-018224 · doc4.xml · derivative · entry 6 Domzalski David · CIK 0001727794 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,278 Underlying: Common Stock · 42,278 shares Expires 2027-01-01 F1 · price: Received in or in connection with the merger of Foamix Pharmaceuticals Ltd. ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. ("Menlo"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020. F4 · derivative.exercise_date: The ordinary shares underlying this option vest over a period of four years (25% on January 1, 2018 and 6.25% every three months thereafter) ending March 31, 2021. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 21:56 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Options · Derivative | 35,544 | Not disclosed Strike: $10.20 | Not disclosed |
DisclosureSEC source: 0001209191-20-018224 · doc4.xml · derivative · entry 5 Domzalski David · CIK 0001727794 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,544 Underlying: Common Stock · 35,544 shares Expires 2026-03-01 F1 · price: Received in or in connection with the merger of Foamix Pharmaceuticals Ltd. ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. ("Menlo"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020. F3 · derivative.exercise_date: The ordinary shares underlying this option vest over a period of four years (25% on March 1, 2017 and 6.25% every three months thereafter) ending March 31, 2020. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 21:56 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Options · Derivative | 140,286 | Not disclosed Strike: $12.06 | Not disclosed |
DisclosureSEC source: 0001209191-20-018224 · doc4.xml · derivative · entry 4 Domzalski David · CIK 0001727794 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,286 Underlying: Common Stock · 140,286 shares Expires 2025-11-10 F1 · price: Received in or in connection with the merger of Foamix Pharmaceuticals Ltd. ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. ("Menlo"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 21:56 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Options · Derivative | 11,107 | Not disclosed Strike: $13.48 | Not disclosed |
DisclosureSEC source: 0001209191-20-018224 · doc4.xml · derivative · entry 3 Domzalski David · CIK 0001727794 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,107 Underlying: Common Stock · 11,107 shares Expires 2024-06-09 F1 · price: Received in or in connection with the merger of Foamix Pharmaceuticals Ltd. ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. ("Menlo"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 21:56 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantCommon Stock | 138,102 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-018224 · doc4.xml · nonDerivative · entry 2 Domzalski David · CIK 0001727794 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,952 F2 · shares: Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo. F1 · price: Received in or in connection with the merger of Foamix Pharmaceuticals Ltd. ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. ("Menlo"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 21:56 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantCommon Stock | 53,850 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-018224 · doc4.xml · nonDerivative · entry 1 Domzalski David · CIK 0001727794 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,850 F1 · price: Received in or in connection with the merger of Foamix Pharmaceuticals Ltd. ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. ("Menlo"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 17:38 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Disposition to issuerOptions · Derivative | 240,912 | Not disclosed Strike: $4.03 | Not disclosed |
DisclosureSEC source: 0001209191-20-018194 · doc4.xml · derivative · entry 10 Domzalski David · CIK 0001727794 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 240,912 shares Expires 2030-02-24 F5 · price: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F12 · derivative.exercise_date: The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2021 and 6.25% every three months thereafter) ending March 31, 2024. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 17:38 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Disposition to issuerOptions · Derivative | 170,993 | Not disclosed Strike: $3.77 | Not disclosed |
DisclosureSEC source: 0001209191-20-018194 · doc4.xml · derivative · entry 9 Domzalski David · CIK 0001727794 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 170,993 shares Expires 2029-01-01 F5 · price: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F11 · derivative.exercise_date: The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2020 and 6.25% every three months thereafter) ending March 31, 2023. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 17:38 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Disposition to issuerOptions · Derivative | 70,187 | Not disclosed Strike: $5.06 | Not disclosed |
DisclosureSEC source: 0001209191-20-018194 · doc4.xml · derivative · entry 8 Domzalski David · CIK 0001727794 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 70,187 shares Expires 2028-02-27 F5 · price: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F10 · derivative.exercise_date: The ordinary shares underlying this option vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending March 31, 2022. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 17:38 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Disposition to issuerOptions · Derivative | 327,720 | Not disclosed Strike: $5.76 | Not disclosed |
DisclosureSEC source: 0001209191-20-018194 · doc4.xml · derivative · entry 7 Domzalski David · CIK 0001727794 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 327,720 shares Expires 2027-08-08 F5 · price: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F9 · derivative.exercise_date: The ordinary shares underlying this option vest over a period of four years (25% on August 8, 2018 and 6.25% every three months thereafter) ending September 30, 2021. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 17:38 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Disposition to issuerOptions · Derivative | 71,369 | Not disclosed Strike: $10.22 | Not disclosed |
DisclosureSEC source: 0001209191-20-018194 · doc4.xml · derivative · entry 6 Domzalski David · CIK 0001727794 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 71,369 shares Expires 2027-01-01 F5 · price: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F8 · derivative.exercise_date: The ordinary shares underlying this option vest over a period of four years (25% on January 1, 2018 and 6.25% every three months thereafter) ending March 31, 2021. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 17:38 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Disposition to issuerOptions · Derivative | 60,000 | Not disclosed Strike: $6.04 | Not disclosed |
DisclosureSEC source: 0001209191-20-018194 · doc4.xml · derivative · entry 5 Domzalski David · CIK 0001727794 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 60,000 shares Expires 2026-03-01 F5 · price: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F7 · derivative.exercise_date: The ordinary shares underlying this option vest over a period of four years (25% on March 1, 2017 and 6.25% every three months thereafter) ending March 31, 2020. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 17:38 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Disposition to issuerOptions · Derivative | 236,810 | Not disclosed Strike: $7.14 | Not disclosed |
DisclosureSEC source: 0001209191-20-018194 · doc4.xml · derivative · entry 4 Domzalski David · CIK 0001727794 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 236,810 shares Expires 2025-11-10 F5 · price: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F6 · derivative.exercise_date: The Options vested over a period of four years from November 10, 2015 (25% on the first anniversary of such date and 6.25% every three months thereafter). Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 17:38 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Disposition to issuerOptions · Derivative | 18,750 | Not disclosed Strike: $7.98 | Not disclosed |
DisclosureSEC source: 0001209191-20-018194 · doc4.xml · derivative · entry 3 Domzalski David · CIK 0001727794 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 18,750 shares Expires 2024-06-09 F5 · price: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F4 · derivative.exercise_date: The Options vested over a period of four years from June 9, 2014 (25% on each anniversary of such date). Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 17:38 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Disposition to issuerOrdinary Shares | 233,126 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-018194 · doc4.xml · nonDerivative · entry 2 Domzalski David · CIK 0001727794 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: Represents Foamix restricted stock unit awards ("Foamix RSUs") that were outstanding immediately prior to the Effective Time, each of which by its terms represented a contingent right to receive one Foamix Share. Each Foamix RSU was assumed by Menlo and converted into a restricted stock unit award relating to Menlo Common Stock (an "Adjusted RSU Award") and has the same terms and conditions as applied to the Foamix RSU immediately prior to the Effective Time. The Adjusted RSU Award will settle in the number of shares of Menlo Common Stock equal to the product obtained by multiplying (i) the number of Foamix Shares subject to the Foamix RSU immediately prior to the Effective Time by (ii) the Exchange Ratio. If the CSRs become convertible, each person holding a Foamix RSU immediately prior to the Effective Time will get additional Adjusted RSU Awards based on the additional shares of Menlo Common Stock that each ordinary Foamix Share will get upon conversion of a CSR. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 17:38 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Disposition to issuerOrdinary Shares | 90,902 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-018194 · doc4.xml · nonDerivative · entry 1 Domzalski David · CIK 0001727794 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,126 F1 · price: On March 9, 2020 (the "Closing Date"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the "Merger Agreement"), by and among Menlo Therapeutics Inc., a Delaware corporation ("Menlo"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo ("Merger Sub"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the "Merger"). At the effective time of the Merger (the "Effective Time"), each ordinary share, par value NIS 0.16 per share, of Foamix ("Foamix Shares") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the "Exchange Ratio") of common stock of Menlo ("Menlo Common Stock") and (ii) one contingent stock right (continued in footnote 2) F2 · price: (a "CSR"; and collectively, the "CSRs") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the "CSR Agreement"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the "Merger Consideration"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 16:38 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | GrantOrdinary Shares | 4,705 | $2.68 | $12,597.64 |
DisclosureSEC source: 0001209191-20-015233 · doc4.xml · nonDerivative · entry 1 Domzalski David · CIK 0001727794 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,028 F1 · kind: These shares were acquired under the Foamix Pharmaceuticals Ltd. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2019 and ending on March 2, 2020 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on December 2, 2019 (the first trading day of the offering period). Read SEC document |
| February 24, 2020 Filed Feb 24, 2020 18:38 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | GrantOptions · Derivative | 240,912 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0001209191-20-012195 · doc4.xml · derivative · entry 2 Domzalski David · CIK 0001727794 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,912 Underlying: Ordinary Shares · 240,912 shares Expires 2030-02-24 F3 · security: Each option represents a contingent right to purchase one ordinary share of the issuer. F4 · derivative.exercise_date: The ordinary shares underlying these options vest over a 4 year period, with 25% vesting on the first anniversary of the last day of the calendar quarter in which the grant occurred and 6.25% vesting on the last day of each subsequent calendar quarter, ending March 31, 2024. Read SEC document |
| February 24, 2020 Filed Feb 24, 2020 18:38 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | GrantOrdinary Shares | 103,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-012195 · doc4.xml · nonDerivative · entry 1 Domzalski David · CIK 0001727794 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,323 F1 · security: This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer. F2 · shares: The ordinary shares underlying this restricted share unit award vest over a 4 year period, with 25% vesting on the first anniversary of the last day of the calendar quarter in which the grant occurred and 6.25% vesting on the last day of each subsequent calendar quarter, ending March 31, 2024. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 17:22 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Tax withholdingOrdinary Shares | 2,751 | $3.28 | $9,023.28 |
DisclosureSEC source: 0001209191-20-001237 · doc4.xml · nonDerivative · entry 1 Domzalski David · CIK 0001727794 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,075 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of the restricted share units and does not represent a sale by the Reporting Person. Read SEC document |
| November 29, 2019 Filed Dec 3, 2019 16:32 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | GrantOrdinary Shares | 9,842 | $2.16 | $21,248.88 |
DisclosureSEC source: 0001209191-19-058713 · doc4.xml · nonDerivative · entry 1 Domzalski David · CIK 0001727794 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,826 F1 · kind: These shares were acquired under the Foamix Pharmaceuticals Ltd. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on June 1, 2019 and ending on December 1, 2019 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on June 3, 2019 (the first trading day of the offering period). The reporting person purchased the maximum number of shares permitted by the terms of the ESPP during the offering period. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 16:18 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Tax withholdingOrdinary Shares | 2,256 | $3.07 | $6,925.92 |
DisclosureSEC source: 0001209191-19-051662 · doc4.xml · nonDerivative · entry 1 Domzalski David · CIK 0001727794 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,984 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of the restricted share units and does not represent a sale by the Reporting Person. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 16:27 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | SaleOrdinary Shares | 3,355 | $2.35 | $7,884.25 |
DisclosureSEC source: 0001209191-19-041107 · doc4.xml · nonDerivative · entry 1 Domzalski David · CIK 0001727794 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,240 F1 · security: For administrative reasons, the Reporting Person's then-existing long term incentives were amended in December 2018 to provide that, effective as of January 1, 2019, the vesting of any unvested restricted share units or options that were granted pursuant to such awards shall take place at the end of the calendar quarter in which the award was otherwise scheduled to vest. F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. This sale is mandated by the Issuer's non-discretionary policy that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 16:40 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | SaleOrdinary Shares | 5,096 | $3.75 | $19,110.00 |
DisclosureSEC source: 0001209191-19-023182 · doc4.xml · nonDerivative · entry 1 Domzalski David · CIK 0001727794 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,595 F1 · security: For administrative reasons, the Reporting Person's then-existing long term incentives were amended in December 2018 to provide that, effective as of January 1, 2019, the vesting of any unvested restricted share units or options that were granted pursuant to such awards shall take place at the end of the calendar quarter in which the award was otherwise scheduled to vest. F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. This sale is mandated by the Issuer's non-discretionary policy that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 16:04 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | GrantOption (right to buy) · Derivative | 170,993 | $3.77 Strike: $3.77 | $644,643.61 |
DisclosureSEC source: 0001178913-19-000043 · zk1922432.xml · derivative · entry 2 Domzalski David · CIK 0001727794 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,993 Underlying: Ordinary Shares · 170,993 shares Expires 2029-01-01 F2 · derivative.exercise_date: The ordinary shares underlying these options vest over a period of four years from the end of the calendar quarter in which the grant was made (25% on March 31, 2020, and 6.25% every three months thereafter on the last day of the quarter) ending March 31, 2023, subject to the reporting person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 16:04 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | GrantOrdinary Shares | 73,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-19-000043 · zk1922432.xml · nonDerivative · entry 1 Domzalski David · CIK 0001727794 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,691 F1 · shares: These shares are represented by restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the Issuer. The ordinary shares underlying this restricted share unit award vest over a period of four years from the end of the calendar quarter in which the grant was made (25% on March 31, 2020, and 6.25% every three months thereafter on the last day of the quarter) ending March 31, 2023, subject to the reporting person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 06:06 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | SaleOrdinary Shares | 68 | $4.05 | $275.40 |
DisclosureSEC source: 0001178913-18-003091 · zk1822352.xml · nonDerivative · entry 1 Domzalski David · CIK 0001727794 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,409 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. This sale is mandated by the Issuer's non-discretionary policy that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discre-tionary trade by the reporting person. Read SEC document |
| November 19, 2018 Filed Nov 20, 2018 16:07 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | SaleOrdinary Shares | 5,036 | $3.90 | $19,640.40 |
DisclosureSEC source: 0001178913-18-003004 · a1822313.xml · nonDerivative · entry 1 Domzalski David · CIK 0001727794 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,477 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. This sale is mandated by the Issuer's non-discretionary policy that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discre-tionary trade by the reporting person. Read SEC document |
| November 08, 2018 Filed Nov 13, 2018 06:13 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | SaleOrdinary Shares | 2,062 | $4.58 | $9,443.96 |
DisclosureSEC source: 0001178913-18-002897 · a11822261.xml · nonDerivative · entry 1 Domzalski David · CIK 0001727794 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,513 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. This sale is mandated by the Issuer's non-discretionary policy that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 17:18 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | SaleOrdinary Shares | 601 | $5.81 | $3,491.81 |
DisclosureSEC source: 0001178913-18-002609 · a1822129.xml · nonDerivative · entry 1 Domzalski David · CIK 0001727794 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,575 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. This sale is mandated by the Issuer's non-discretionary policy that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 16:05 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | SaleOrdinary Shares | 67 | $5.67 | $379.89 |
DisclosureSEC source: 0001178913-18-002498 · zk1822078.xml · nonDerivative · entry 1 Domzalski David · CIK 0001727794 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,176 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. This sale is mandated by the Issuer's non-discretionary policy that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| August 08, 2018 Filed Aug 9, 2018 16:07 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | SaleOrdinary Shares | 8,238 | $5.68 | $46,791.84 |
DisclosureSEC source: 0001178913-18-002365 · zk1822018.xml · nonDerivative · entry 1 Domzalski David · CIK 0001727794 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,243 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of re-stricted share units. This sale is mandated by the Issuer's non-discretionary policy that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 16:09 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | SaleOrdinary Shares | 602 | $5.10 | $3,070.20 |
DisclosureSEC source: 0001178913-18-002034 · zk1821866.xml · nonDerivative · entry 1 Domzalski David · CIK 0001727794 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,481 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of re-stricted share units. This sale is mandated by the Issuer's non-discretionary policy that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 14:20 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | SaleOrdinary Shares | 67 | $5.26 | $352.42 |
DisclosureSEC source: 0001178913-18-001847 · zk1821776.xml · nonDerivative · entry 1 Domzalski David · CIK 0001727794 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,083 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of re-stricted share units. This sale is mandated by the Issuer's non-discretionary policy that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| May 08, 2018 Filed May 10, 2018 17:30 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | GrantOptions · Derivative | 70,187 | $0.00 Strike: $5.06 | $0.00 |
DisclosureSEC source: 0001178913-18-001598 · zk1821661.xml · derivative · entry 2 Domzalski David · CIK 0001727794 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,187 Underlying: Ordinary Shares · 70,187 shares Expires 2028-02-27 F4 · security: Each option represents a contingent right to purchase one ordinary share of the issuer. F1 · date: The equity incentive grants were approved by the Issuer's board of directors on the recommendation of a committee of the board on February 27, 2019, subject to shareholder approval as required under the Israeli Companies Law. The Issuer's shareholders approved the equity incentive grants on May 8, 2018. F5 · derivative.exercise_date: The ordinary shares underlying these options vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending February 27, 2022. Read SEC document |
| May 08, 2018 Filed May 10, 2018 17:30 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | GrantOrdinary Shares | 23,396 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-18-001598 · zk1821661.xml · nonDerivative · entry 1 Domzalski David · CIK 0001727794 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,150 F1 · date: The equity incentive grants were approved by the Issuer's board of directors on the recommendation of a committee of the board on February 27, 2019, subject to shareholder approval as required under the Israeli Companies Law. The Issuer's shareholders approved the equity incentive grants on May 8, 2018. F2 · shares: The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending February 27, 2022. F3 · price: This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 12:28 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | SaleOrdinary Shares | 602 | $5.08 | $3,058.16 |
DisclosureSEC source: 0001178913-18-001110 · zk1821457.xml · nonDerivative · entry 1 Domzalski David · CIK 0001727794 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,754 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. This sale is mandated by the Issuer's non-discretionary policy that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 11:37 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | SaleOrdinary Shares | 66 | $5.95 | $392.70 |
DisclosureSEC source: 0001178913-18-000759 · a1821323.xml · nonDerivative · entry 1 Domzalski David · CIK 0001727794 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,356 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. This sale is mandated by the Issuer's non-discretionary policy that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| January 02, 2018 Filed Jan 24, 2018 20:24 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Tax withholdingOrdinary Shares | 2,397 | $5.98 | $14,334.06 |
DisclosureSEC source: 0001178913-18-000263 · a1821071.xml · nonDerivative · entry 2 Domzalski David · CIK 0001727794 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,422 F3 · shares: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of restricted share units. Read SEC document |
| January 01, 2018 Filed Jan 24, 2018 20:24 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Exercise / conversionRestricted Share Units · Derivative | 5,948 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001178913-18-000263 · a1821071.xml · derivative · entry 3 Domzalski David · CIK 0001727794 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,948 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer. F4 · derivative.exercise_date: The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on January 1, 2018 and 6.25% every three months thereafter) ending January 1, 2021. F4 · derivative.expiration_date: The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on January 1, 2018 and 6.25% every three months thereafter) ending January 1, 2021. F5 · balance_after: This class of restricted share units is included in Column 5 of Table I above. Read SEC document |
| January 01, 2018 Filed Jan 24, 2018 20:24 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Exercise / conversionOrdinary Shares | 5,948 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-18-000263 · a1821071.xml · nonDerivative · entry 1 Domzalski David · CIK 0001727794 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,819 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer. F2 · balance_after: The issuer's method of reporting restricted share units has been revised to report such grants in Table I rather than as previously reported in Table II. Accordingly, this amount includes (i) 23,192 ordinary shares previously reported in Table I of the reporting person's Form 3, (ii) 5,948 ordinary shares underlying restricted share units that vested on January 1, 2018 and (ii) 113,679 ordinary shares subject to unvested restricted share units that were previously reported in Table II of the reporting person's Form 3 as a derivative security. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.